Evidence map›Paper›PMID 37085729›Full record

ArticleJournal of cancer research and clinical oncology2023

In vitro and in vivo study on the treatment of non-small cell lung cancer with radionuclide labeled PD-L1 nanobody.

Mengqin Zhu, Jiajia Zhang, Mengdie Yang, Han Zhang, Tao Xu, Fei Kan, Xiaoyi Zhang, Shenghong Zhang, Yuzhen Yin, Fei Yu

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Preclinical evaluation of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  2. Preclinical evaluation and preliminary clinical study ofCancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mengqin Zhu *Shanghai Clinical College, Anhui Medical University, Shanghai, 200040, China.
Jiajia Zhang *Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yanchang Road, Shanghai, 200040, China.
Mengdie Yang *Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yanchang Road, Shanghai, 200040, China.
Han ZhangDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yanchang Road, Shanghai, 200040, China.
Tao XuSmart-Nuclide Biopharma Co. Ltd, No. 218 Xing-Hu Rd., Suzhou, 215125, China.
Fei KanSmart-Nuclide Biopharma Co. Ltd, No. 218 Xing-Hu Rd., Suzhou, 215125, China.
Xiaoyi ZhangDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yanchang Road, Shanghai, 200040, China.
Shenghong ZhangShanghai Clinical College, Anhui Medical University, Shanghai, 200040, China.
Yuzhen YinDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yanchang Road, Shanghai, 200040, China.
Fei YuShanghai Clinical College, Anhui Medical University, Shanghai, 200040, China. yufei_021@163.com.
Shanghai Tenth People's Hospital · CNTongji University · CN

Funding

National Natural Science Foundation of China 82071956
6 · The paper itself

Abstract

purposeNanobodies have become promising carriers due to excellent in vivo properties. Radiopharmaceutical therapy targeting programmed cell death ligand 1 (PD-L1) is an effective therapeutic strategy. Our study aimed to explore therapeutic efficacy of

methods

results

conclusion

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsB7-H1 AntigenCell Line, TumorHumansIodine RadioisotopesRadiopharmaceuticalsB7-H1 AntigenIodine-131Iodine RadioisotopesRadiopharmaceuticalsNanobodyNon-small cell lung cancersProgrammed cell death ligand 1Radiopharmaceutical

Identifiers

PMID37085729
PMCPMC11797396
OpenAlexW4366606219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.